Free fatty acids promote hepatic lipotoxicity by stimulating TNF-α expression via a lysosomal pathway

Hepatology

Volumn 40, Issue 1, 2004, Pages 185-194

  Feldstein, Ariel E ^a   Werneburg, Nathan W ^a   Canbay, Ali ^a   Guicciardi, Maria Eugenia ^a   Bronk, Steven F ^a   Rydzewski, Robert ^b   Burgart, Laurence J ^a   Gores, Gregory J ^a,c  

^a Mayo Clinic   (United States)

^b CELERA   (United States)

^c MAYO CLINIC COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; CYSTEINE PROTEINASE; FATTY ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BAX; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME INACTIVATION; ENZYME RELEASE; FATTY LIVER; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; LIVER CYTOSOL; LIVER LYSOSOME; LIVER PROTECTION; LIVER TOXICITY; METABOLIC SYNDROME X; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT;

ANIMALS; ANTIGENS, CD; BCL-2-ASSOCIATED X PROTEIN; CATHEPSIN B; CELLS, CULTURED; CYTOSOL; DIET; DRUG COMBINATIONS; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; HUMANS; LIVER; LYSOSOMES; MICE; MICE, KNOCKOUT; NF-KAPPA B; OLEIC ACID; PALMITATES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SEVERITY OF ILLNESS INDEX; TISSUE DISTRIBUTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3042824524     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20283     Document Type: Article

References (30)

1. Friedman JM. Obesity in the new millennium. Nature 2000;404:632-634.
2. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
3. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
4. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000;6:998-1003.
5. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999;245:621-625.
6. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389:610-614.
7. Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luster MI, et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999;117:942-952.
8. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. HEPATOLOGY 2003;37:343-350.
9. Memon RA, Grunfeld C, Feingold KR. TNF-alpha is not the cause of fatty liver disease in obese diabetic mice. Nat Med 2001;7:2-3.
10. Unger RH. Lipotoxic diseases. Annu Rev Med 2002;53:319-336.
11. Unger RH. The physiology of cellular liporegulation. Annu Rev Physiol 2003;65:333-347.
12. Unger RH, Orci L. Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta 2002;1585:202-212.
13. Nehra V, Angulo P, Buchman A, Lindor KD. Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig Dis Sci 2001;46:2347-2352.
14. Acosta D, Wenzel DG. Injury produced by free fatty acids to lysosomes and mitochondria in cultured heart muscle and endothelial cells. Atherosclerosis 1974;20:417-426.
15. Guicciardi ME, Deussing J, Miyoshi H, Bronk SF, Svingen PA, Peters C, et al. Cathepsin B contributes to TNF-alpha-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J Clin Invest 2000;106:1127-1137.
16. Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk S, Gores G. Diet associated hepatic steatosis sensitizes to fas mediated liver injury in mice. J Hepatol 2003;39:978-983.
17. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A 2000;97:1784-1789.
18. Shumabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced B-cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 1998;95:2498-2502.
19. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-260.
20. Higuchi H, Bronk SF, Taniai M, Canbay A, Gores GJ. Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2/DR5 expression and sensitizes the liver to TRAIL- mediated cytotoxicity. J Pharmacol Exp Ther 2002;303:461-467.
21. Higuchi H, Bronk SF, Takikawa Y, Werneburg N, Takimoto R, El-Deiry W, et al. The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis. J Biol Chem 2001;276:38610-38618.
22. Miyoshi H, Rust C, Roberts PJ, Burgart LJ, Gores GJ. Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology 1999;117:669-677.
23. Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, et al. Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003;125:437-443.
24. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002;2:647-656.
25. Chaisson ML, Brooling JT, Ladiges W, Tsai S, Fausto N. Hepatocyte-specific inhibition of NF-kappaB leads to apoptosis after TNF treatment, but not after partial hepatectomy. J Clin Invest 2002;110:193-202.
26. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-455.
27. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-1850.
28. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. HEPATOLOGY 2002;35:373-379.
29. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001;293:1673-1677.
30. Hirosumi J, Tuncman G, Chang L, Gorgun CZ, Uysal KT, Maeda K, et al. A central role for JNK in obesity and insulin resistance. Nature 2002;420:333-336.